Celebrating Lp(a) Awareness Day 2022 today!

Home - Reagents

Celebrating Lp(a) Awareness Day 2022 today!

Randox are raising awareness for Lipoprotein(a), we want to drive awareness on tests that are available to you to decrease the risk of stroke, heart attack or other heart diseases.

Lp(a) is a risk factor for atherosclerosis and related diseases including CHD and stroke. It is increasingly recognised as the strongest known genetic risk factor for premature coronary artery disease. The biggest challenge that exists surrounding Lp(a) measurement is the heterogeneity of the apolipoprotein(a) isoforms, resulting in the underestimation or overestimation of Lp(a) concentrations.

Benefits of the Randox Lp(a) assay

WHO/IFCC reference material – The Randox Lp(a) assay is calibrated in nmol/l and traceable to the WHO/IFCC reference material (IFCC SRM 2B) and provides an acceptable bias compared with the Northwest Lipid Metabolism Diabetes Research Laboratory (NLMDRKL) gold standard method.

Dedicated calibrator & control available – Five point calibrator with accuracy-based assigned target values (in nmol/l) is available, accurately reflecting the heterogeneity of the apo(a) isoforms. Dedicated Lp(a) control is available offering a complete testing package.

Excellent correlation – A correlation coefficient of r=0.995 was displayed when the Randox method was compared against other commercially available methods.

Excellent precision – The Randox Lp(a) assay displayed a within run precision of <2.54%.

Liquid ready-to-use – The Randox Lp(a) assay is available in a liquid ready-to-use format for convenience and ease-of-use.

Applications available – Instrument-specific settings can be provided for a wide range of clinical chemistry analysers.

 

The biggest challenge that exists surrounding Lp(a) measurement is the heterogeneity of the apo(a) isoforms, resulting in the underestimation or overestimation of Lp(a) concentrations. In immunoassays, the variable numbers of repeated KIV-2 units in Lp(a) act as multiple epitopes. This is where standardisation across calibrators is vital. Unless the calibrants do have the same range of isoforms as test samples, those with higher numbers of the KIV-2 repeat, will represent with an overestimation in Lp(a) concentrations and those with smaller numbers of the KIV-2 repeat, will represent with an underestimation. The smaller isoforms are strongly associated with higher Lp(a) concentrations. Lack of standardisation of the calibrant would result in an underestimation of Lp(a) associated CVD risk. It is important to note that an Lp(a) immunoassay employing isoform insensitive antibodies does not exist.

 

DID YOU KNOW?

Lp(a) has been identified to be a key risk factor for cardiovascular complications in individuals with COVID-19!

It is well documented that pre-existing comorbidities such as diabetes and CVD are associated with greater severity and higher fatality rates in those with COVID-19.  Those with either baseline elevated Lp(a) or those whose Lp(a) levels increased following infection from COVID-19, or both, maybe at a significantly increased risk of developing thromboses. Elevated Lp(a) levels may cause acute destabilisation of pre-existing but quiescent, atherosclerotic plaques, which could induce an acute myocardial infarction or stroke.

Identifying any possible health conditions that would relate to early signs of stroke, heart attack or other heart diseases will allow you to make any decisions on an appropriate diet, lifestyle changes and early treatment to reduce your risk of further problems.

For more information about Lp(a):

Visit our website: Lipoprotein(a) [Lp(a)] | Reagents | Randox Laboratories

Or email: marketing@randox.com

 

Want to know more?

Contact us or visit Reagents

Contact Us
Visit the Reagents Page

Lp(a) Calibrator

Lp(a) Control

Lipid EQA Scheme

Reagents Resource Hub


RX daytona/imola /daytona plus/monaco

Randox Acetaminophen Reagent

We develop a range of applications for the RX daytona/ imola/ daytona plus/ monaco analysers so that laboratories worldwide can enjoy the benefits of freedom of choice from an independent manufacturer, Randox Laboratories. We have a range of assays available for the RX daytona/ imola/ daytona plus/ monaco, and we are always developing more applications. If you don’t see the application you are looking for, please contact us to request an application.

All kits are produced to international standard and have ISO 13485 accreditation.

Existing customers can access IFU’s through Powerline.

Rx daytona/imola /daytona plus/monaco - Reagents
AUTOIMMUNE
Complement Component 3 CRP Full Range (0.3-160mg/l)IgECRP
Complement Component 4 CRP High Sensitivity IgG
IgAIgMRheumatoid Factor
BASIC METABOLIC PROFILE
Calcium Creatinine EnzymaticPotassiumCO2 Total
Creatinine (Jaffe)SodiumChlorideGlucose
Urea
BONE
Alkaline PhosphataseCalciumPhosphorusTotal Protein
CARDIAC
CholesterolCRP Full Range (0.3-160mg/l)Direct LDL CholesterolMyoglobin
CK-MBCRP High Sensitivity Heart-Type Fatty Acid Binding Protein (H-FABP) sLDL
CK-NACDigoxinHomocysteineTriglycerides
CRP Direct HDL CholesterolLipoprotein (a)
COMPREHENSIVE METABOLIC PROFILE
Albumin Direct BilirubinCreatinine (Jaffe)Sodium
Alkaline PhosphataseCalcium GlucoseTotal Bilirubin
ALTChlorideLactateTotal Protein
AST (GOT) CO2 Total Potassium Urea
DIABETES
CholesterolDirect HDL CholesterolGlycerol Ranbut (Hydroxybutyrate)
Creatinine EnzymaticDirect LDL Cholesterol HbA1c/Hb Total Protein
Creatinine (Jaffe)FructosamineMicroalbumin Triglycerides
Cystatin CGlucoseNEFA (Non-Esterified Fatty Acids)Urinary Protein
ELECTROLYTES
Calcium CO2 Total Magnesium Sodium (Direct / Nondirect)
Chloride (Direct / Nondirect)LithiumPotassium (Direct / Nondirect)
HAEMOLYTIC ANAEMA
G-6-P-DHHaptoglobinLDH
HEPATIC FUNCTION
AlbuminCholinesteraseHaptoglobin Total Bilirubin
AldolaseComplement C3 IgA Total Protein
Alkaline PhosphataseComplement C4IgG Transferrin
Alpha-1 AntitrypsinDirect Bilirubin IgMTransthyretin (Prealbumin)
ALTGamma GTIron (UIBC)Ammonia
GLDHLeucine Arylamidase (LAP)AST (GOT) Glycerol
LDH
INFLAMMATION AND INFECTION
Acid PhosphataseASOLactateAlpha-1Acid Glycoprotein
CRPRheumatoid Factor
LIPIDS
Apolipoprotein A-IApolipoprotein C-IICholesterolLipoprotein (a)
Apolipoprotein A-II Apolipoprotein C-IIIDirect HDL CholesterolsLDL
Apolipoprotein BApolipoprotein EDirect LDL CholesterolTriglycerides
NEONATAL SCREENING
Alpha-1 AntitrypsinCRP Full Range (0.3-160mg/l) IgECRP
CRP High SensitivityTransthyretin (Prealbumin)
NEUROLOGICAL DISORDERS (CSF)
IgAIgGIgM
NUTRITIONAL STATUS
AlbuminIronMagnesiumTransferrin
Copper Iron (UIBC)PotassiumTransthyretin (Prealbumin)
FerritinLipaseTIBCZinc
PANCREATIC FUNCTION
AmylaseLDHPancreatic AmylaseGlucose
Lipase
RENAL FUNTION
Albumin Creatinine EnzymaticIgGSodium
AmmoniaCreatinine (Jaffe)LDHPhosphorus (Inorganic)
Beta-2 MicroglobulinCystatin CMagnesium Urinary Protein
CalciumGlucose Microalbumin Urea
Chloride HbA1c/HbPotassiumUric Acid
VETERINARY
Albumin Cholinesterase (Butyryl)HDLSuperoxide Dismutase (Ransod)
Alkaline phosphataseCK-NAC Iron (UIBC) Sodium
ALT (GPT) CO2 Total Lactate Therapeutic drugs
AldolaseCopper Lactate dehydrogenase Total Protein
Ammonia CreatinineLDLTriglycerides
AmylaseCRPLipaseUrea
AST (GOT) Canine CRP Magnesium Uric Acid
Bile acidsFructosamine NEFA (Non-esterified fatty acids)Urinary protein
BilirubinGamma-GT Phosphorus (Inorganic) Zinc
CalciumGLDH PotassiumChloride
GlucoseRanbut (Hydroxybutyrate)CholesterolGlycerol
Glutathione Peroxidase (Ransel)
TOXICOLOGY
Therapeutic Drugs
AcetaminophenGentamicinPhenytoinValproic Acid
CarbamazepineLithiumSalicylateDigoxin
PhenobarbitolTheophyline
Drugs of Abuse
BarbituratesCocaine metaboliteEthanolOpiates
BenzodiazepinesEDDPMethadoneCannabinoids
EcstasyMethamphetamine
SPECIFIC PROTEINS
Alpha-1 AntitrypsinASOCystatin CIgM
Alpha-1 Acid GlycoproteinBeta-2 MicroglobulinFerritinLipoprotein (a)
Apolipoprotein A-I CeruloplasminFructosamineMicroalbumin
Apolipoprotein A-II Complement C3 HaptoglobinMyoglobin
Apolipoprotein B Complement C4HbA1c/Hb Rheumatoid Factor
Apolipoprotein C-II CRP IgA Transthyretin (Prealbumin)
Apolipoprotein C-IIICRP Full Range (0.3-160mg/l)IgETransferrin
Apolipoprotein ECRP High Sensitivity IgG
RESEARCH
Antioxidants
AlbuminGlutathione Reductase TIBCUric Acid
BilirubinGlutathione Peroxidase (Ransel)Total Antioxidant StatusFerritin
Superoxide Dismutase (Ransod)Transferrin
Biotechnology
GlutamateGlutamine
Food and Wine Testing
Acetic AcidCopperGlycerolMalic Acid
Ammonia Glucose Iron Potassium
CalciumGlucose/FructoseL-Lactic AcidTotal Antioxidant Status

 


SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper

Randox Logo

30 June 2021

SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper Download

COVID-19, the disease caused by SARS-CoV-2, is an infectious disease caused by a newly discovered coronavirus. While many of whom become infected by the disease will experience mild to moderate cold or flu-like symptoms, those with health complications – such as autoimmune diseases, asthma, heart disease and diabetes – are at risk of developing serious illness and adverse outcomes.

As of September 2021, over 228 million COVID-19 cases have been confirmed worldwide, with an estimated one in six patients experiencing complications which could be life threatening, with over £116 billion spent by the UK government alone on measures to combat the disease. This drastic spending has been mirrored across the globe, with the significant economic burden expected to be suffered for generations to come.

The whitepaper provides a brief overview of the COVID-19 pandemic, before discussing vascular abnormalities and associated complications brought on by the virus, such as multi-system disfunction, acute respiratory disease syndrome (ARDS) and hepatic, renal & cardiovascular function.

 

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


Why does Randox sponsor Equine Sports events?

Why does Randox sponsor Equine Sports?

1 September 2021: Why does Randox sponsor Equine Sports?

Some may be wondering, why is a healthcare company so invested in the equine industry? Why would they sponsor the world’s most famous steeplechase – The Randox Grand National?

It’s a labour of love… Peter FitzGerald’s fond attachment to the equestrian world, together with 40 years’ experience in the in vitro diagnostics industry, was the perfect match.

Clinical diagnostics is at the heart of Randox and our experience and expertise has paved the way for the development of innovative and accurate diagnostic products for Equine Health.

You could say ‘it runs in our blood.’

With 70% of all medical decisions based on the analysis of blood, Randox are set to release the VeraSTAT-V, a stable-side Equine Serum Amyloid A test device designed to detect levels of inflammation in horse blood in a matter of minutes.

The ability to quickly detect and monitor your horse’s health, at the stable side, brings huge benefits to both horse and owner. Early detection of inflammatory states means treatment plans can start sooner, recovery periods are shorter, and the horse can return to work healthy much earlier.

When performance is key, monitoring inflammation is vital.

Whether it’s detecting inflammation related to joint injury, or screening for infection before or after transport, competition or surgery, the VeraSTAT-V is a valuable means to monitor Equine Health.

At Randox, we have enjoyed a long-standing partnership with the Jockey Club and will continue to deliver innovative diagnostics solutions to the Equine Industry for the years ahead.

Interested in finding out more? 

For all Equine SAA and/or Veterinary related inquiries, please email marketing@randox.com or visit www.randox.com/veraSTAT-V for more information.

QUALITY CONTROL

REAGENTS

RX SERIES


Syphilis

Reagents | Syphilis

Key Benefits

Quantative and qualitative results available

For choice and convenience

Excellent stability

Stable to expiry when stored at 2-8°C

Randox Syphilis

  • Treponema Pallidum Haemagglutination Assay (TPHA) method
  • Liquid ready-to-use reagents
  • Stable to expiry when stored at 2-8°C
  • Qualitative or quantitative results
Cat NoSize    
SY1480100TEnquireKit Insert RequestMSDSBuy Online
SY1481200TEnquireKit Insert RequestMSDSBuy Online
SY1478100T (Card test)Buy Online

Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers.  Contact us to enquire about your specific analyser.

What is the Syphilis assay used for?

Syphilis is a chronic, contagious and often congenital venereal disease caused by Treponema pallidum. Infection results from contact with moist surfaces, originating in lesions of the epithelial tissue of the skin and mucous membranes. If untreated the disease may result in irreversible changes in the cardiovascular and nervous system. Syphilis remains a disease of high incidence, despite advances in modern antibiotic therapy.

Clinical Chemistry Panel

For more information or to view more reagents within the clinical chemistry panel, please click here

Rapid Tests / Serology Panel

For more information or to view more reagents within the rapid tests / serology panel, please click here


Roche Cobas

Randox Acetaminophen Reagent

Applications for Roche Cobas 4000 / 6000 / 8000

We develop a range of applications for the Roche Cobas Series (4000 / 6000 / 8000) analysers so that laboratories worldwide can enjoy the benefits of freedom of choice from an independent manufacturer, Randox Laboratories.

Applications available for Roche Cobas

We have 69 reagents available for the Roche Cobas Series (4000 / 6000 / 8000), and are always developing more. If you don’t see the application you are looking for, please email us to request an application. All kits are produced to international standard and have ISO 13485 accreditation.

=

Albumin
Aldolase
Alkaline Phosphatase
ALT
Ammonia
Apolipoprotein A-I
Apolipoprotein B
Apolipoprotein C-II
Apolipoprotein C-III
Apolipoprotein E
AST
ß2 Microglobulin
Bile Acids
Bilirubin
Calcium
Carbamazepine
Cholesterol Total
Cholesterol HDL
Cholesterol LDL
Cholesterol sdLDL
Cholinesterase (Butyryl)
CK-MB
CO2 Total

Copper
Creatinine
CRP
CRP Canine
Cystatin C
D-3 Hydroxybutyrate (Ranbut)
Ethanol
Ferritin
Fructosamine (Glycated Protein)
G6PDH
Gamma GT
GLDH
Glucose
Glutamate
Glutathione Peroxidase (Ransel)
Glutathione Reductase
Glycerol
Haptoglobin
HbA1c
IgA
IgE
IgG
IgM

Iron
L-Lactate
LD Pyruvate-Lactate
Lipase
Lipoprotein (a)
Magnesium
Microalbumin
NEFA
Potassium
Rheumatoid Factor (RF)
Sodium
Superoxide Dismutase (Ransod)
Total Antioxidant Status(TAS)
Total Iron Binding
Capacity (TIBC)
Total Protein
Transferrin
Transthyretin (Prelbumin)
Triglycerides
Urea
Uric Acid
Urinary Protein
Zinc

Email Us

Get in touch with Randox via email at reagents@randox.com

Need Instructions?

Download your kit insert for free on our online portal

Buy Online

Order your reagents kits online by visiting our online store 


Evidence Series Resource Hub

Evidence Series | Resource Hub

  • Brochures
  • Flyers
  • Videos
  • Blogs
  • Scientific Posters
  • Whitepapers

Evidence

Evidence Investigator

Evidence MultiSTAT

Evidence+

Evidence Evolution

Biochip Technology Explained

Evidence series Overview

Discover more about the Evidence series

 

Cytokines Flyer

DIKI Renal Flyer

A4 Renal Flyer

AKI Covid-19 Flyer

Evidence Investigator - Molecular Diagnostic Testing

Evidence MultiSTAT Demonstration

Evidence Evolution - World's Most Advanced Immunoanalyser

Evidence Investigator - Myco 9 Array, Step By Step

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE SIMULTANEOUS DETECTION OF CANCER BIOMARKERS ON THE RANDOM ACCESS, FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A DUPLEX BIOCHIP ASSAY FOR THE SIMULTANEOUS DETECTION OF ANTI-THYROGLOBULIN AND ANTI-THYROID PEROXIDASE ANTIBODIES ON THE FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF NEW BIOCHIP ARRAYS FOR THE DETERMINATION OF BIOMARKERS RELATED TO ACUTE KIDNEY INJURY APPLIED TO THE EVIDENCE INVESTIGATOR ANALYSER

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY FOR THE DETECTION OF PARATHYROID HORMONE APPLIED TO THE EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A HIGHLY MULTIPLEXED MOLECULAR ASSAY FOR DETECTION OF INFECTION IN CF AIRWAYS

Repeatability and within-laboratory precision were assessed (n=80): Assay Repeatability Within-laboratory precision CV (%) CV (%) VCAM-1 4.5 6.8 ICAM-1 5.6 8.8 ESEL 12.8 16.6 PSEL 3.5 4.7 LSEL 5.7 8.2 17.096, 097.105RDRT DEVELOPMENT OF A BIOCHIP ARRAY FOR THE DETECTION OF ADHESION MOLECULES ON THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY UNAFFECTED BY DHEA-S INTERFERENCE FOR THE ACCURATE MEASUREMENT OF SERUM PROGESTERONE

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE RAPID, SIMULTANEOUS DETECTION OF PEPSINOGEN I, PEPSINOGEN II AND GASTRIN 17, ON THE NEW RANDOM ACCESS, FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

CLINICAL EVALUATION OF A RAPID FULLY-AUTOMATED MULTIPLEX BIOCHIP ARRAY FOR STROKE DIAGNOSIS

DEVELOPMENT OF A NEW BIOCHIP ARRAY APPLIED TO THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER FOR THE SIMULTANEOUS MEASUREMENT OF TSH, FREE T4 AND FREE T3

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY FOR THE MEASUREMENT OF TOTAL 25-HYDROXYVITAMIN D IN SERUM AND THE ACCURATE CLASSIFICATION OF VITAMIN D STATUS

DEVELOPMENT OF A BIOCHIP ASSAY FOR THE DETECTION OF THYROXINE-BINDING GLOBULIN (TBG) ON THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

GENETIC DIAGNOSIS OF MONOGENIC OR POLYGENIC FAMILIAL HYPERCHOLESTEROLEMIA IN NORTHERN IRELAND: EVALUATION OF THE RANDOX FH ARRAYS IN COMBINATION WITH THE RANDOX 6SNP POLYGENIC HYPERCHOLESTEROLEMIA ARRAY

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE SIMULTANEOUS MEASUREMENT OF DISTINCT FATTY ACID-BINDING PROTEINS (FABPs)

DEVELOPMENT OF A NEW ENZYME-LINKED IMMUNOSORBENT ASSAY KIT TO DETECT NGAL IN HUMAN SERUM AND ITS APPLICATION TO CHRONIC KIDNEY DISEASE

SCREENING AND SELECTION OF ANTIBODIES FOR THE DETECTION OF MIP-1 ALPHA AND ITS APPLICATION TO THE STUDY OF CHRONIC KIDNEY DISEASE

DEVELOPMENT OF A 4-PLEX BIOCHIP ARRAY FOR THE EARLY DETECTION OF CHRONIC KIDNEY DISEASE

DEVELOPMENT OF A THIRD GENERATION TSH ASSAY ON THE NEW RANDOM ACCESS EVIDENCE EVOLUTION FULLY AUTOMATED BIOCHIP ANALYSER

APPLICATION OF THE NEW RANDOM ACCESS, FULLY AUTOMATED BIOCHIP ANALYSER EVIDENCE EVOLUTION TO SIMULTANEOUSLY MEASURE ANALYTES RELATED TO ENDOCRINE FUNCTION

SARS-CoV-2 Vascular & Multi-System Dysfunction


Beckman Coulter AU

Randox Acetaminophen Reagent

Applications for Beckman Coulter AU Series

We develop a range of applications for the Beckman Coulter AU Series (400 / 480 / 600 / 640 / 680 / 2700 / 5400 / 5800 / DxC700AU) analysers so that laboratories worldwide can enjoy the benefits of freedom of choice from an independent manufacturer, Randox Laboratories.

Beckman Coulter AU Series Applications

We have 89 reagents available for the Beckman Coulter AU (400 / 480 / 600 / 640 / 680 / 2700 / 5400 / 5800 / DxC700AU) analysers, and are always developing more. If you don’t see the application you are looking for, please contact us to request an application. All kits are produced to international standard and have ISO 13485 accreditation.

Albumin
Aldolase
Alkaline Phosphatase
ALT
Ammonia
Amylase
Apolipoprotein A-I
Apolipoprotein A-II
Apolipoprotein B
Apolipoprotein C-II
Apolipoprotein C-III
Apolipoprotein E
ASO
AST
ß2 Microglobulin
Bile Acids
Bilirubin
Calcium
Carbamazepine
Cholesterol Total
Cholesterol HDL
Cholesterol LDL
Cholesterol sdLDL
Cholinesterase (Butyryl)
CK-MB
CK-NAC
CO2
Total
Complement C3
Complement C4

Copper
Creatinine
CRP
CRP Canine
CRP Full Range
CRP High Sensitivity
Cystatin C
D-3 Hydroxybutyrate(Ranbut)
Digoxin
Ethanol
Ferritin
Fructosamine(Glycated Protein)
G6PDH
Gamma GT
GLDH
Glucose
Glutathione Peroxidase(Ransel)
Glutathione Reductase
Glycerol
Haptoglobin
HbA1c
Homocysteine
IgA
IgE
IgG
IgM
Iron
L-Lactate
LD Lactate – Pyruvate
LD Pyruvate – Lactate

Lipase
Lipoprotein (a)
Magnesium
Microalbumin
Myoglobin
NEFA
Phenobarbital
Phenytoin
Phosphorus
Potassium
Rheumatoid Factor (RF)
Sodium
Superoxide Dismutase (Ransod)
Total Antioxidant Status (TAS)
Total Iron Binding
Capacity (TIBC)
Total Protein
Transferrin
Transthyretin (Prealbumin)
Triglycerides
Urea
Uric Acid
Urinary Protein
Valproic Acid
Zinc

Need Instructions?

Download kit inserts for free on our online portal

Email Us

Get in touch with Randox via email at reagents@randox.com

Buy Online

Order reagents kits online by visiting our online store 


Cardiology Reagents Panel

Randox Cardiology Reagents Panel

Randox is a leading provider of diagnostic reagents for the assessment of cardiovascular disease risk. Our extensive menu of cardiac biomarkers within the cardiology reagents panel include: routine lipid tests such as Homocysteine, hsCRP, Apo A-I, Apo A-II, Apo B and Lp(a), as well as, unique assays for cardiac risk assessment including sdLDL Cholesterol, Apo C-II, Apo C-III and Apo E. Check out our benefits below.

Download our Cardiology & Lipids Brochure

Benefits

  • Unique reagents enable impeccable patient care with an expanded profile for cardiac risk assessment
  • Wide measuring ranges for accurate detection of abnormal levels
  • Liquid ready-to-use reagents for convenience, and we also offer lyophilised reagents
  • Applications available for a wide range of clinical chemistry analysers
  • Strong correlation to reference methods for trusted results

Randox Cardiology Reagents

Risk Assessment

  • CK-MB useful in patients with chest pain; Creatine Kinase is an enzyme produced in many different types of cells, of which high levels indicate muscle trauma or damage.
  • Myoglobin, a small protein which leaks out of muscle cells after injury, is also considered a biomarker for the detection of Myocardinal Infraction.
  • Routine lipid tests to determine the patient’s cholesterol and triglyceride levels – HDL Cholesterol, LDL Cholesterol, Total Cholesterol and Triglycerides
  • Independent risk assessment tests such as sdLDL Cholesterol and Lipoprotein(a) to determine any genetic factors which may increase their risk of CVD. Please note, this is necessary even for patients who have good cholesterol levels
  • Secondary tests, such as High Sensitivity CRP, in addition to risk assessment markers and lipid evaluation – secondary tests are important in predicting future cardiac events of individuals with no previous history of CVD and those deemed healthy as a result of primary tests; approximately half of all heart attacks occur in patients classified as low risk. In addition, they can also be used to evaluate the risk of a recurrent cardiac event
  • Speciality tests include
    • Homocysteine – elevated levels of homocysteine have been linked to various disease states including CVD. Extremely high levels are found in patients with homocystinuria, of which many suffer from early arteriosclerosis.
Download our Cardiology & Lipids Brochure

Email Us

Get in touch with your local sales representative via email at reagents@randox.com

Need Instructions?

Kit Inserts are available to download for free on our online portal

Buy Online

Order your cardiology kits today by visiting our online store 


Lipid Testing Panel

Lipid Panel Testing Panel | Reagents

Introducing The Randox Lipids Panel

Cardiovascular disease (CVD) caused by atherosclerosis (arteriosclerosis) is the leading cause of morbidity and mortality in Western countries1. Atherosclerosis involves the hardening and narrowing of vessels in the systemic system. This process originates from the build-up of fatty deposits through a process known as atherogenesis. If the build-up increases, plaque rupturing may occur which may lead to myocardial infarction2.

The mission of the National Lipid Association (NLA) “is to enhance the practice of lipid management in clinical medicine”.  NLA advocate advancing the current lipid testing profile. The current lipid panel consists of testing LDL cholesterol, HDL cholesterol and triglycerides, which only detects approximately 20% of all atherosclerotic cardiovascular disease (ASCVD) patients.  Advanced lipid testing is recommended to optimise patient treatment3.

Current Challenges

icons +7

75% of circulatory risk factors are preventable4

 

icons +14

1 in 4 deaths in the US is attributed to heart disease6

Lipids-01

6 million people in the UK suffer from narrowing of the heart arteries5

How Can Randox Help With The Current Challenges

  • Risk Assessment using Randox lipid reagents

As the current lipid panel consists of testing LDL cholesterol, HDL cholesterol and triglycerides, which only detects approximately 20% of all coronary artery disease (CAD) patients, advanced lipid testing is recommended to optimise patient treatment. The Randox lipid profile encompasses niche and superior performance assays for the detection of conventional risk factors, as well as emerging biomarkers associated with further risk.

Lipids-06

Apolipoprotein C-III (Apo C-III)
A niche product from Randox, Apo C-III deficiency has shown to increase the rate of triglyceride clearance from plasma by up to 7 fold. Apo C-III levels have been reported higher in several conditions such as type 2 diabetes, hyperbilirubinemia and decreased thyroid function.

Lipids-04

Apolipoprotein E (Apo E)
A niche product from Randox, Apo E has been found to have an association with neurodegenerative conditions such as Alzheimer’s Disease and Multiple Sclerosis. A deficiency in Apo E gives rise to high levels of serum cholesterol and triglycerides, leading to premature atherosclerosis

Lipids-05

HDL3 Cholesterol (HDL3-C)
A niche product from Randox, HDL3-C, a subclass of HDL-C, has an inverse correlation with CVD risk. Several clinical studies indicate that measuring these HDL-C subclasses better reflects primary and secondary CHD risk than measurement of total HDL-C, making it a significant independent biomarker for better risk profiling when used together with other risk markers.

Lipids-07

Lipoprotein (a) (Lp(a))
A unique product from Randox, Lp(a) has proven to have a causal role in the premature development of atherosclerosis and CVD as elevated Lp(a) levels associate robustly and specifically with increased CVD risk. The Randox Lp(a) assay is one of the only methodologies on the market that detects the non-variable part of the Lp(a) molecule and therefore suffers minimal size related bias.

sdLDl-C

Small-dense LDL Cholesterol (sdLDL-C)
A niche product from Randox, sdLDL-C, a subtype of LDL cholesterol, can more readily permeate the inner arterial wall. Research indicates that individuals with a predominance of sdLDL-C have a 3-fold increased risk of myocardial infarction.

  • Benefits of Randox Lipid Reagents
icons ++

Liquid ready-to-use assays
The Randox lipid assays are available in a liquid ready-to-use format for convenience and ease of use. (The Triglycerides kit is also available in a lyophilised format).

icons ++6

Wide measuring ranges
The Randox lipid assays can comfortably detect levels outside of the healthy range for the accurate detection of abnormal levels, offering peace of mind in patient samples.

icons ++3

Excellent correlation with standard methods
The Randox lipid assays display excellent correlations when compared against standard methods, offering trust and confidence in results.

icons ++4

Applications are available
Applications are available detailing instrument-specific settings for the convenient use of the Randox lipid assays on a wide range of clinical chemistry analysers.

  • Randox Lipid Reagents
  • Circulatory Health Problems
  • Tips to improve circulatory health

Cardiovascular disease (CVD) refers to disease of the heart or blood vessels. Heart disease encompasses a number of diseases that affect the heart. In contrast, vascular disease encompasses a number of diseases that affect the blood vessels. Circulatory health problems are the result of vascular disease. Developing problems within the vascular system can go undetermined and in some patients the problem may only become apparent when they experience a heart attack or stroke 7.

Lipids-01

Atherogenesis and Atherosclerosis

Atherogenesis is a circulatory disease whereby atheromas are formed (plaque build-up) within the artery.  Plaque is a combination of cholesterol, fat, calcium, lipids and other substances within the blood stream.  As time progresses, the plaque hardens, narrowing the arteries.  This is known as atherosclerosis. Consequently, blood flow through the narrowed artery is reduced, limiting the supply of blood to vital organs and bodily tissues.  As atherogenesis can affect any artery within the body, different diseases may develop based on the artery that is affected.  Such diseases include: coronary heart/artery disease, carotid artery disease, peripheral artery disease and chronic kidney disease8.

Lipids-02

Plaque Rupture

As atherogenesis and atherosclerosis causes plaque to build up and harden within the arteries precipitating thrombi, blood flow to the heart, brain, or the lower extremities is obstructed (depending on the artery affected).  This can further develop into coronary heart/artery disease (heart), ischemic stroke (brain) or peripheral vascular disease (lower extremities).  However, the most common and most discussed of these manifestations is coronary heart/artery disease9.  These manifestations occur when the plaque ruptures.  The risk of the plaque rupturing is determined by the type of plaque (composition) rather than the size of the plaque (volume) as only plaques that are rich in soft extracellular lipids are rupture-prone (vulnerable).  Whilst most plaque ruptures are small causing an acute coronary event, the actual vulnerability of the plaque may change over time.  Luckily, the vulnerable plaque components are most likely to regress with treatment10.

icons +7

Myocardial Infarction

The processes of atherogenesis, atherosclerosis and plaque rupturing, if left undetected can a myocardial infarction (MI) or “heart attack” if the plaque build-up has occurred in the coronary artery11. MI occurs when the blood supply to heart is completely blocked by the formation of a clot or a blockage due to a loose piece of atheroma (plaque rupturing). If the blood supply to the heart is blocked the cells in the heart begin to die due to the lack of oxygen, causing chest pain (angina). The extent of the blockage and the amount of heart muscle affected will determine whether this malfunction will affect the hearts ability to pump blood12. The signs of atherogenesis, atherosclerosis and plaque rupturing can be subtle, and most heart attack victims may only feel symptoms in the days leading up to the attack. For 80% of people, the first sign of a heart attack is angina. Other symptoms to be aware of are shortness of breath, anxiety, sweating, light-headedness and temporary changes in vision 11.

icons +18

Exercise

Regular exercise has a major effect on your circulation and cardiovascular health. Moderate levels of exercise can increase blood flow and reduce the risk of poor circulatory health conditions such as atherosclerosis. Exercise promotes good circulation as it strengthens the heart muscles, lowing the resting heart rate and preventing the build-up of plaque in the arteries. It is important for those with current circulation problems to be vigilant while exercising to ensure they are not over exerting themselves13.

icons +19

Know your healthy fats

Diet changes are important for improving circulatory health. Eating a variety of foods such as lean meats, vegetables, fruits, legumes and whole grains will aid in lowering lipid levels and keep them low. It is recommended that more unsaturated fats are consumed in comparison to saturated fats, as saturated fats raise sdLDL-C levels which can lead to an increased risk of atherosclerosis. On the other hand, unsaturated fats such as monounsaturated or polyunsaturated fats may increase HDL levels and are known as being ‘heart-healthy’. It is recommended to find healthier alternatives for certain foods such as butter and oil14.

smoking icon

Stop Smoking

Smoking can cause circulatory problems in several ways. Most notably it can cause the carotid arteries (arteries which supply oxygen to the brain) to become filled with plaque. Also, smoking can cause PAD by reducing adequate blood supply to the limbs which can lead to leg pain and possibly amputation. Quitting smoking has been proven to have positive effects on circulation: just 20 minutes after a cigarette, blood pressure decreases and oxygen levels return to normal. Within 24 hours, the chance of a heart attack will have already decreased and after 48 hours, nerve endings deeded by the habit are expected to regenerate, with sense of taste and smell improving also. A year after quitting, the risk of coronary heart disease (CHD) will be halved. After 15 years, a quitter’s risk of CHD is now similar to that of a person who has never smoked14.

Related Products

Cardiology Testing Panel

Featured Reagent Home

Reagents Resource Hub

  • References

    [1] Burnett, John R. Lipids, Lipoproteins, Atherosclerosis and Cardiovascular Disease. National Center for Biotechnology Information (NCBI). [Online] Clin Biochem Rev., 25 February 2004. [Cited: 3 December 2018.] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1853363/.

    [2] Zimmermaann, Kim Ann. Circulatory Systenm: Facts, Function & Diseases. Live Science. [Online] 16 March 2018. [Cited: 3 December 2018.] https://www.livescience.com/22486-circulatory-system.html.

    [3] National Lipid Association. National Lipid Association Releases Updated Recommendations on the Use of PCSK9 Inhibitors at the 15th Annual Scientific Session. [Online] no date. [Cited: 3 December 2018.] https://www.lipid.org/nla/national-lipid-association-releases-updated-recommendations-use-pcsk9-inhibitors-15th-annual.

    [4] World Heart Federation. Driving Sustainable Action for Circulatory Health: Whitepaper for Circulatory Health. [Online] Global Coarlition for Circulatory Health, no date. [Cited: 30 November 2018.] https://www.world-heart-federation.org/wp-content/uploads/2018/11/White-Paper-for-Circulatory-Health.pdf.

    [5] British Heart Foundation. Research into atherosclerosis: 4 scientists talk about their work. [Online] no date. [Cited: 30 November 2018.] https://www.bhf.org.uk/informationsupport/heart-matters-magazine/research/atherosclerosis..

    [6] Centers for Disease Control and Prevention. Heart Disease Facts. [Online] 28 November 2017. [Cited: 4 December 2018.] https://www.cdc.gov/heartdisease/facts.htm.

    [7] Cardiovascular Disease. NHS. [Online] NHS UK, September 15, 2018. [Cited: November 30, 2018.] https://www.nhs.uk/conditions/cardiovascular-disease/

    [8] National Heart, Lunch, and Blood Institute. Atherosclerosis. [Online] no date. [Cited: 28 November 2018.] https://www.nhlbi.nih.gov/health-topics/atherosclerosis.

    [9] Fog Bentzon, Jacob, et al. Mechanisms of Plaque Formation and Rupture. Circulation Research. [Online] 6 June 2014. [Cited: 29 November 2018.] https://www.ahajournals.org/doi/abs/10.1161/circresaha.114.302721.

    [10] Falk, E. Why do plaques rupture? National Center for Biotechnology Information. [Online] Circulation, December 1992. [Cited: 29 November 2018.] https://www.ncbi.nlm.nih.gov/pubmed/1424049.

    [11] MedBroadcast. Heart Attack (Myocardial Infarction, MI). [Online] no date. [Cited: 30 November 2018.] https://medbroadcast.com/condition/getcondition/heart-attack.

    [12] Harvard Health Publications. Heart Attack (Myocardial Infarction. [Online] 10 September 2018. [Cited: 30 November 2018.] https://www.drugs.com/health-guide/heart-attack-myocardial-infarction.html.

    [13] Bergeson Becco, Laine. How Exercise Affects Circulation (and Vice Versa). Experience Life. [Online] June 2017. [Cited: 4 December 2018.] https://experiencelife.com/article/how-exercise-affects-circulation-and-vice-versa/.

    [14] Mayo Clinic. Top 5 lifestykle changes to improve your cholesterol. [Online] 11 August 2018. [Cited: 4 December 2018.] https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/reduce-cholesterol/art-20045935.


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.